Key takeaways
Emtriva (emtricitabine) and Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) are both medications used to treat HIV. They both contain emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), which helps prevent the virus from making copies of itself. However, they differ in several ways. Emtriva is a single medication that must be used in combination with other HIV antiretrovirals, while Complera is a complete single-tablet regimen that includes two additional medications: rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and tenofovir, another NRTI. Emtriva is available as a capsule and an oral solution, whereas Complera is only available as a tablet that must be taken with food. Complera is not a first-choice option because newer medications have fewer side effects. Common side effects of Emtriva include nausea and fatigue, while Complera can cause mood changes and insomnia. Additionally, Complera has more drug interactions, especially with medications for tuberculosis, seizures, and stomach acid, and it is not recommended for people with kidney problems.
